George Vlachogiannis, Executive Editor of Cancer Control at Sage Publishing, shared a post on LinkedIn:
“Breast cancer metastasis to the spleen is a rare event. Due to this rarity few studies have evaluated clinicopathological characteristics of this patient population. A recent retrospective study published in Cancer Control reports clinicopathological features and prognoses of breast cancer patients with splenic metastases, based on a cohort of ~1,000 patients with metastatic breast cancer.
Spleen metastases were identified in 18 patients (1.7%), were associated with diffuse multiple organ metastases, and with a survival prognosis of less than a year.”
Authors: Xiaofeng Xie et al.
